On the other hand, sorafenib used in association with azacytidine in ineligible de novo FTL3-mutated AML and in R/R FLT3-ITD-mutated AML, has shown a CR rate of 26% and 27% respectively and a CR/CRi rate of 70% and 43% (141, 142). Here, FLT3 is linked to acute myeloid leukemia.